



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Seema GARDE, et al.

FOR

PHARMACEUTICAL PREPARATIONS AND METHODS FOR INHIBITING

AND METHODS FOR INHIBITI

TUMORS

SERIAL NO.

09/977,406

FILED

October 15, 2001

EXAMINER

HOLLERAN, ANNE L.

ART UNIT

1642

CONFIRMATION NO.

4176

ATTORNEY DOCKET NO.

CLWZ 2 00147

INFORMATION DISCLOSURE STATEMENT

MAIL STOP AMENDMENT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In accordance with 37 C.F.R. §§ 1.56, 1.97, 1.98 and MPEP § 609, applicant(s) submit(s) the following Disclosure Statement concerning art of which the applicant(s) is (are) aware. A copy of PTO-1449 is enclosed herewith.

This Information Disclosure Statement is not intended to constitute an admission that any patent, publication or other information referred to herein or submitted herewith is "prior art" for this invention unless specifically designated as such.

In accordance with the United States Patent and Trademark Office OG Notice dated 05 August 2003, waiving the requirement under 37 C.F.R. §1.98(a)(2)(i), for submitting a copy of each cited U.S. patent and U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003, Applicant(s) has not enclosed copies of the cited U.S. patents and applications with this Disclosure.

v Did not receive any NIPLS.

In accordance with 37 C.F.R. §1.97(g) and (h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.

Under § 1.98(a)(3), no concise explanation of relevance is required for information that is in the English language. Accordingly, the enclosed require(s) no further explanation (or no translation is available).

further explanation (or no translation is available). Consideration of the appropriate paragraph(s) indicated below is respectfully requested: WITHIN THREE MONTHS OF FILING: Under § 1.97(b)(1), this Information Disclosure Statement is being filed within three months of the filing date of the application. Although it is believed no fee is necessary, any deficiency in fees should be charged to Deposit Account No. 06-0308. BEFORE FIRST OFFICE ACTION: Under § 1.97(b)(3), this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. Although it is believed no fee is necessary, any deficiency in fees should be charged to Deposit Account No. 06-0308. INTERNATIONAL SEARCH REPORT: Under § 1.97(e)(1), the undersigned certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. Although it is believed no fee is necessary, any deficiency in fees should be charged to Deposit Account No. 06-0308. Under § 1.97(c)(2), this \boxtimes BEFORE FINAL ACTION/WITH FEE: information shall be considered if filed before the mailing date of a final action if accompanied by a fee in the amount of \$180.00 as required by §1.17(p). Accordingly, the necessary fee accompanies this Information Disclosure Statement. Any overpayment or deficiency can be charged to Deposit Account No. 06-0308. PRIORITY CLAIM: The attached PTO 1449 Form includes all patents, publications, or other information previously cited by or submitted to the Office in one or more prior applications from which the present application claims priority. These one or more prior applications are identified in the papers accompanying the filing of this application. In accordance with § 609 MPEP, only copies of art not previously submitted are enclosed.

It is respectfully requested that the attached document(s) be considered and officially cited in examination of this application.

FAY, SHARPE, FAGAN, MINNICH & McKEE, LLP

Respectfully submitted,

November 16,2004

Ann M. Skerry Reg. No. 45,655 1100 Superior Avenue Seventh Floor Cleveland, OH 44114-2518 216/861-5582

Certify that this Information Disclosure Statement and accompanying document(s) are being deposited with the United States Postal Service as First Class mail under 37 C.F.R. 1.8, addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below. transmitted to facsimile number under 37 C.F.R. 1.8 on the date indicated below. deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated below and is addressed to: Mail Stop Amendment, Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450. Express Mail Label No.: Date November 16, 2004 Crystal D. Tidrick

N:\CLWZ\200147\cdt0000122V001.doc

Examiner Signature	k .	Date Considered	

Mbikay, M., et al. (DNA 6(1):23-29, 1987 (Gene Bank Accession No. AAA36635)

Makinen, M., et al. (Eur. J. Biochem. 264(2):407-414, 1999 (Gene Bank Accession No. CAB39325)

Akiyama, K., et al., Nippon Hoigaku Zasshi 39(2), pgs. 181-186, 1985 (Gene Bank Accession No.

AQ

AR

AS

ΑT AU ΑV 1209281A)